Bacillus Subtilis and Enterococcus Faecium Probiotic Plus Lipid-Lowering Therapy for Hypertriglyceridemic Acute Pancreatitis: A Prospective RCT
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 180 participants.
Also called NCT07720232
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 180 participants
- Sponsor
- Jianyin Zhou
- Registry
-
NCT07720232
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07720232. Randomized; double masking; primary purpose treatment. Start 2026-01-18 (actual); primary completion 2028-01-18 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Bacillus Subtilis and Enterococcus Faecium Probiotic Plus Lipid-Lowering Therapy for Hypertriglyceridemic Acute Pancreatitis: A Prospective RCT
- Condition
- Hypertriglyceridemic Acute Pancreatitis
- Condition
- Acute Pancreatitis, Hypertriglyceridemia-induced
- Condition
- Hyperlipidemia
- Intervention (Drug)
- Live Combined Bacillus subtilis and Enterococcus faecium Enteric-coated Capsules (LCBE)
- Intervention (Drug)
- Standard Care (in control arm)
- Lead sponsor
- Jianyin Zhou
Record details
- Record id
cardio:ct-nct07720232- Content hash
fbf090ba90457399e6dea6d6519ac09ca8e48f3bcf30dc05223740d4eb12b7f7